Masato Kishida
President
UI
United Immunity, Co., Ltd.
The startup develops lipid nanoparticles (LNPs) that specifically target myeloid cells, enabling the direct delivery of therapeutic agents to macrophages and dendritic cells. This technology facilitates the development of treatments for cancer, autoimmune diseases, fibrosis, and infectious diseases by enhancing the precision of drug delivery.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$13.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops lipid nanoparticles (LNPs) that specifically target myeloid cells, enabling the direct delivery of therapeutic agents to macrophages and dendritic cells. This technology facilitates the development of treatments for cancer, autoimmune diseases, fibrosis, and infectious diseases by enhancing the precision of drug delivery.